European Commission Approves SYLVANT® (siltuximab) as a Treatment for Patients with Multicentric Castleman’s Disease (MCD)
- EMEA Innovative Medicine
- European Commission Approves SYLVANT® (siltuximab) as MCD Treatment
European Commission Approves SYLVANT® (siltuximab) as MCD Treatment
- X (Twitter)
Copy link